|
 |
|
|
CytoLVT-S™ - Large Volume Clinical Transfection System |
|
Introduction
 View CytoLVT-S™ Data Sheet (81 KB)
View Cytoporation® Medium Data Sheet (101 KB)
|
|
CytoLVT-S™ is a large volume ex vivo / in vitro
cell transfection system based on
electroporation technology.
Cyto Pulse's intellectual property
portfolio in cell transfection, including patents and patents pending,
enables direct scale-up of basic reasearch to clinical and industrial applications without increasing process complexity.
Usage models include:
- Personal vaccines (immunotherapy)
- General vaccines (immunotherapy)
- Gene correction (gene therapy)
- Industrial Recombinant Product
- Protein production
|
|
|
|
CytoLVT-S™ is made up of of three
parts: the CCEP-100 waveform generator, large 20 ml transfection
chambers, and low conductivity Cytoporation® Medium.
It is a standalone system with touch screen and USB key
interface. An external computer is not required for operation.
|
| Technology
The large volume system consists of a large uniform-field static electroporation chamber and has the advantage of no lengthy pulsing protocols, motors, cooling apparatus or pumps as is the case with continuous flow electroporation systems.
Up to a few billion cells are treated uniformly under the same conditions at the same instant.
Complex waveforms such as variable amplitude Pulse Agile® are easily applied.
|
 |
|
Chamber volumes are flexible and can range from 2 ml to 20 ml.
Transfection protocols readily scale-up from research level transfections in standard 4 mm
electroporation cuvettes to CytoLVT-S™ 20 ml 4 mm gap transfection without modification.
Male and female leur lock connectors are located on the top with relief valve located in the center to allow for
sterile cell handling.
The chambers are sterile and individually packaged and labeled.
For commercial use the chambers may be reused. For clinical use the chambers are single use and disposable.
|
| Clinical Cancer Immunotherapy, Phase I Human Trial
The Mayo Clinic conducted Phase I clinical trials of stage IV patients with malignant melanoma. Their approach consisted of isolating RNA from melanoma tissue, transfecting in vitro amplified mRNA into patient dendritic cells (DC) with Cyto Pulse technology, then administring those DCs back into patients subcutaneously. This process was concluded to be a safe, potentially viable treatment therapy.
Mayo Clinic Study Results (2006)
 Mayo Clinic Study Results (2004)
|
|
This system is available under direct license agreement with Cyto Pulse.
Please Contact Cyto Pulse for Additional Information
Part No. 015-100690
|
|
)